Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis
BackgroundDanlou tablets exert auxiliary advantages in treating coronary heart disease (CHD), but a summary of evidence-based proof is lacking. This study aims to systematically evaluate Danlou tablets in treating CHD from two aspects, including efficacy and safety.MethodsBy a thorough retrieval of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1100006/full |
| _version_ | 1797809793920925696 |
|---|---|
| author | WeiLi Mao Peng Lu Renhong Wan Kaili Mao Yanzhu Lv Jie Hu Zhenling Fu Jun Wang |
| author_facet | WeiLi Mao Peng Lu Renhong Wan Kaili Mao Yanzhu Lv Jie Hu Zhenling Fu Jun Wang |
| author_sort | WeiLi Mao |
| collection | DOAJ |
| description | BackgroundDanlou tablets exert auxiliary advantages in treating coronary heart disease (CHD), but a summary of evidence-based proof is lacking. This study aims to systematically evaluate Danlou tablets in treating CHD from two aspects, including efficacy and safety.MethodsBy a thorough retrieval of the four English databases, namely, PubMed, The Cochrane Library, Embase, and Web of Science, and the four Chinese databases, namely, CNKI, Wanfang, VIP database, and China Biomedical Literature Service System, we found all randomized controlled trials (RCTs) related to Danlou tablets in treating CHD. The retrieval time was from the construction of the database to April 2022. We engaged two researchers to screen the studies, extract the required data, and assess the risk of bias. We then used RevMan5.3 and STATA.14 software to conduct a meta-analysis. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to evaluate the quality of outcome indicators.ResultsSeventeen RCTs involving 1,588 patients were included. The meta-analysis results are displayed as follows: clinical treatment effect [risk ratio (RR) = 1.22, 95% confidence interval (CI): 1.16, 1.28, P < 0.00001], angina pectoris duration [MD = −0.2.15, 95% CI: −2.91, −1.04, P < 0.00001], angina pectoris frequency [standard mean difference (SMD) = −2.48, 95% CI: −3.42, −1.54, P < 0.00001], angina pectoris degree [SMD = −0.96, 95% CI: −1.39, −0.53, P < 0.0001], TC [MD = −0.71, 95% CI: −0.92, −0.51, P < 0.00001], TG [MD = −0.38, 95% CI: −0.53, −0.22, P < 0.00001], low-density lipoprotein cholesterol [MD = −0.64, 95% CI: −0.76, −0.51, P < 0.00001], high-density lipoprotein cholesterol [MD = 0.16, 95% CI: 0.11, 0.21, P < 0.00001], and adverse events [RR = 0.46, 95% CI: 0.24, 0.88, P = 0.02].ConclusionThe current evidence suggests that the combination of Danlou tablets and Western medicine can enhance the efficacy of CHD and does not increase adverse events. However, because of the limited number and quality of the included studies, the results of our study should be treated with caution. Further large-scale RCTs are necessary to verify the benefits of this approach. |
| first_indexed | 2024-03-13T06:58:08Z |
| format | Article |
| id | doaj.art-9c84720e08c8486ba6f143f75b771e2a |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-03-13T06:58:08Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-9c84720e08c8486ba6f143f75b771e2a2023-06-07T05:21:20ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-06-011010.3389/fcvm.2023.11000061100006Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysisWeiLi Mao0Peng Lu1Renhong Wan2Kaili Mao3Yanzhu Lv4Jie Hu5Zhenling Fu6Jun Wang7Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, ChinaDepartment of Pharmacy, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, ChinaSchool of Acupuncture and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaDepartment of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, ChinaSchool of Acupuncture and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaDepartment of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, ChinaDepartment of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, ChinaDepartment of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, ChinaBackgroundDanlou tablets exert auxiliary advantages in treating coronary heart disease (CHD), but a summary of evidence-based proof is lacking. This study aims to systematically evaluate Danlou tablets in treating CHD from two aspects, including efficacy and safety.MethodsBy a thorough retrieval of the four English databases, namely, PubMed, The Cochrane Library, Embase, and Web of Science, and the four Chinese databases, namely, CNKI, Wanfang, VIP database, and China Biomedical Literature Service System, we found all randomized controlled trials (RCTs) related to Danlou tablets in treating CHD. The retrieval time was from the construction of the database to April 2022. We engaged two researchers to screen the studies, extract the required data, and assess the risk of bias. We then used RevMan5.3 and STATA.14 software to conduct a meta-analysis. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to evaluate the quality of outcome indicators.ResultsSeventeen RCTs involving 1,588 patients were included. The meta-analysis results are displayed as follows: clinical treatment effect [risk ratio (RR) = 1.22, 95% confidence interval (CI): 1.16, 1.28, P < 0.00001], angina pectoris duration [MD = −0.2.15, 95% CI: −2.91, −1.04, P < 0.00001], angina pectoris frequency [standard mean difference (SMD) = −2.48, 95% CI: −3.42, −1.54, P < 0.00001], angina pectoris degree [SMD = −0.96, 95% CI: −1.39, −0.53, P < 0.0001], TC [MD = −0.71, 95% CI: −0.92, −0.51, P < 0.00001], TG [MD = −0.38, 95% CI: −0.53, −0.22, P < 0.00001], low-density lipoprotein cholesterol [MD = −0.64, 95% CI: −0.76, −0.51, P < 0.00001], high-density lipoprotein cholesterol [MD = 0.16, 95% CI: 0.11, 0.21, P < 0.00001], and adverse events [RR = 0.46, 95% CI: 0.24, 0.88, P = 0.02].ConclusionThe current evidence suggests that the combination of Danlou tablets and Western medicine can enhance the efficacy of CHD and does not increase adverse events. However, because of the limited number and quality of the included studies, the results of our study should be treated with caution. Further large-scale RCTs are necessary to verify the benefits of this approach.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1100006/fullDanlou tabletcoronary heart diseaserandomized controlled trialmeta-analysiscomplementary alternative therapy |
| spellingShingle | WeiLi Mao Peng Lu Renhong Wan Kaili Mao Yanzhu Lv Jie Hu Zhenling Fu Jun Wang Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis Frontiers in Cardiovascular Medicine Danlou tablet coronary heart disease randomized controlled trial meta-analysis complementary alternative therapy |
| title | Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis |
| title_full | Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis |
| title_short | Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis |
| title_sort | efficacy and safety of danlou tablets in traditional chinese medicine for coronary heart disease a systematic review and meta analysis |
| topic | Danlou tablet coronary heart disease randomized controlled trial meta-analysis complementary alternative therapy |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1100006/full |
| work_keys_str_mv | AT weilimao efficacyandsafetyofdanloutabletsintraditionalchinesemedicineforcoronaryheartdiseaseasystematicreviewandmetaanalysis AT penglu efficacyandsafetyofdanloutabletsintraditionalchinesemedicineforcoronaryheartdiseaseasystematicreviewandmetaanalysis AT renhongwan efficacyandsafetyofdanloutabletsintraditionalchinesemedicineforcoronaryheartdiseaseasystematicreviewandmetaanalysis AT kailimao efficacyandsafetyofdanloutabletsintraditionalchinesemedicineforcoronaryheartdiseaseasystematicreviewandmetaanalysis AT yanzhulv efficacyandsafetyofdanloutabletsintraditionalchinesemedicineforcoronaryheartdiseaseasystematicreviewandmetaanalysis AT jiehu efficacyandsafetyofdanloutabletsintraditionalchinesemedicineforcoronaryheartdiseaseasystematicreviewandmetaanalysis AT zhenlingfu efficacyandsafetyofdanloutabletsintraditionalchinesemedicineforcoronaryheartdiseaseasystematicreviewandmetaanalysis AT junwang efficacyandsafetyofdanloutabletsintraditionalchinesemedicineforcoronaryheartdiseaseasystematicreviewandmetaanalysis |